Advanced

Complement C4d-specific antibodies for the diagnosis of lung cancer

Ajona, Daniel; Okrój, Marcin LU ; Pajares, María J.; Agorreta, Jackeline; Lozano, María D.; Zulueta, Javier J.; Verri, Carla; Roz, Luca; Sozzi, Gabriella and Pastorino, Ugo, et al. (2018) In Oncotarget 9(5). p.6346-6355
Abstract

Development of molecular markers that help to identify high-risk individuals or diagnose indeterminate pulmonary nodules could have a major impact on lung cancer clinical management. In this study, we evaluated the diagnostic potential of a newly-developed ELISA that specifically detects complement C4d. We measured this marker in five independent cohorts of plasma and bronchoalveolar lavage samples from lung cancer patients and controls. In case-control studies, the area under the ROC curve for the diagnosis of lung cancer was 0.82 (95%CI = 0.72-0.92) in plasma samples, and 0.80 (95%CI = 0.69 to 0.90) in bronchoalveolar lavage fluids. In a set of plasma samples from the MILD CT-screening trial, the assay was unable to discriminate... (More)

Development of molecular markers that help to identify high-risk individuals or diagnose indeterminate pulmonary nodules could have a major impact on lung cancer clinical management. In this study, we evaluated the diagnostic potential of a newly-developed ELISA that specifically detects complement C4d. We measured this marker in five independent cohorts of plasma and bronchoalveolar lavage samples from lung cancer patients and controls. In case-control studies, the area under the ROC curve for the diagnosis of lung cancer was 0.82 (95%CI = 0.72-0.92) in plasma samples, and 0.80 (95%CI = 0.69 to 0.90) in bronchoalveolar lavage fluids. In a set of plasma samples from the MILD CT-screening trial, the assay was unable to discriminate between asymptomatic high-risk individuals with or without early stage lung cancer. On the contrary, in two independent cohorts of individuals with indeterminate pulmonary nodules, plasma samples from patients with lung cancer nodules presented higher levels of C4d than those from patients with benign nodules. Using a target population of patients with 8 to 30 mm nodules, the test identified likely benign lung nodules with 84% negative predictive value and 54% positive predictive value, at 89% specificity and 44% sensitivity. In conclusion, the specific determination of C4d may serve as an adjunct to current clinical practice in the diagnosis of indeterminate pulmonary nodules.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biomarker, Complement C4d, Diagnosis, Indeterminate pulmonary nodules, Lung cancer
in
Oncotarget
volume
9
issue
5
pages
10 pages
publisher
Impact Journals, LLC
external identifiers
  • scopus:85040687768
ISSN
1949-2553
DOI
10.18632/oncotarget.23690
language
English
LU publication?
yes
id
fa45a6be-7358-4fd1-8a44-66dca82c08be
date added to LUP
2018-02-05 10:51:52
date last changed
2018-02-08 10:46:41
@article{fa45a6be-7358-4fd1-8a44-66dca82c08be,
  abstract     = {<p>Development of molecular markers that help to identify high-risk individuals or diagnose indeterminate pulmonary nodules could have a major impact on lung cancer clinical management. In this study, we evaluated the diagnostic potential of a newly-developed ELISA that specifically detects complement C4d. We measured this marker in five independent cohorts of plasma and bronchoalveolar lavage samples from lung cancer patients and controls. In case-control studies, the area under the ROC curve for the diagnosis of lung cancer was 0.82 (95%CI = 0.72-0.92) in plasma samples, and 0.80 (95%CI = 0.69 to 0.90) in bronchoalveolar lavage fluids. In a set of plasma samples from the MILD CT-screening trial, the assay was unable to discriminate between asymptomatic high-risk individuals with or without early stage lung cancer. On the contrary, in two independent cohorts of individuals with indeterminate pulmonary nodules, plasma samples from patients with lung cancer nodules presented higher levels of C4d than those from patients with benign nodules. Using a target population of patients with 8 to 30 mm nodules, the test identified likely benign lung nodules with 84% negative predictive value and 54% positive predictive value, at 89% specificity and 44% sensitivity. In conclusion, the specific determination of C4d may serve as an adjunct to current clinical practice in the diagnosis of indeterminate pulmonary nodules.</p>},
  author       = {Ajona, Daniel and Okrój, Marcin and Pajares, María J. and Agorreta, Jackeline and Lozano, María D. and Zulueta, Javier J. and Verri, Carla and Roz, Luca and Sozzi, Gabriella and Pastorino, Ugo and Massion, Pierre P. and Montuenga, Luis M. and Blom, Anna M. and Pio, Ruben},
  issn         = {1949-2553},
  keyword      = {Biomarker,Complement C4d,Diagnosis,Indeterminate pulmonary nodules,Lung cancer},
  language     = {eng},
  number       = {5},
  pages        = {6346--6355},
  publisher    = {Impact Journals, LLC},
  series       = {Oncotarget},
  title        = {Complement C4d-specific antibodies for the diagnosis of lung cancer},
  url          = {http://dx.doi.org/10.18632/oncotarget.23690},
  volume       = {9},
  year         = {2018},
}